Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

80.07 +1.45 (+1.84%)
Delayed Quote Updated: 12:37 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
From Disc Medicine Inc
Via GlobeNewswire
Today's Top US Stock Movers: Small-Cap Gainers and Losers ↗
Via Chartmill
Today's Top Market Movers: Silence Therapeutics Jumps 126%, CL Workshop Slides 43% ↗
Via Chartmill
News headline image
Disc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission ↗
Disc Medicine (NASDAQ:IRON) said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP)... 
Via MarketBeat
Gap-Up and Gap-Down Movers for Oct. 19, 2026 ↗
Via Chartmill
Premarket Movers Oct. 19: Disc Medicine Jumps 51.62%, Rubico Falls 33.84% ↗
Via Chartmill
News headline image
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
From Disc Medicine Inc
Via GlobeNewswire
News headline image
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges ↗
Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company... 
Via MarketBeat
News headline image
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>